Rituximab injection vs radiation for eye lymphoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This study compares two treatments for a slow-growing eye lymphoma called MALT lymphoma. One uses a drug called rituximab injected directly into the tumor, and the other uses targeted radiation. The goal is to see which works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with MALT lymphoma in the eye area (the ocular adnexa).
- The lymphoma is localized and has not spread beyond the eye area (stages T1 to T3).
- You have not had any prior radiation, chemotherapy, or other treatments for this lymphoma.
- You do not have serious eye diseases like uncontrolled glaucoma, cataracts that affect your vision badly, or other conditions that need surgery.
- You are not pregnant or breastfeeding, and you have no other serious illnesses like advanced heart, kidney, or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for a slow-growing eye lymphoma called MALT lymphoma: a targeted injection (rituximab) directly into the tumor versus low-dose radiation. The goal is to see which is safer and works better, while avoiding whole-body side effects.
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
This trial tests a combination of low-dose radiation and an oral targeted therapy (orelabrutinib) for patients with a slow-growing type of lymphoma called MALT lymphoma. The goal is to see if this approach can effectively treat the disease while reducing side effects.
This trial tests whether a short course of low-dose radiation (12 Gy in 6 sessions) is safe and effective for treating indolent (slow-growing) non-Hodgkin lymphoma in the eye socket (orbit). It may help control the disease while minimizing side effects.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
Hear when a new Primary Ocular Adnexal MALT Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.